On December 31, 2021, upon recommendation of the Nominating and Corporate Governance committee of the board of directors of Cytek Biosciences, Inc., the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the company, effective December 31, 2021, to fill the newly created directorship, until her successor is elected and qualified, or sooner in the event of her death, resignation or removal. Dr. Imper joins the class of directors whose term expires at the company's 2023 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.97 USD | -0.83% | -2.13% | -34.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.54% | 784M | |
+11.31% | 226B | |
+15.50% | 198B | |
+18.83% | 142B | |
+30.38% | 111B | |
+2.74% | 65.26B | |
+18.31% | 54.36B | |
+4.96% | 50.94B | |
+9.95% | 44.8B | |
+4.27% | 36.8B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Appoints Vera Imper as A Class II Director